RU2017106489A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017106489A3 RU2017106489A3 RU2017106489A RU2017106489A RU2017106489A3 RU 2017106489 A3 RU2017106489 A3 RU 2017106489A3 RU 2017106489 A RU2017106489 A RU 2017106489A RU 2017106489 A RU2017106489 A RU 2017106489A RU 2017106489 A3 RU2017106489 A3 RU 2017106489A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179601 | 2014-08-01 | ||
| EP14179601.1 | 2014-08-01 | ||
| PCT/EP2015/067534 WO2016016382A1 (en) | 2014-08-01 | 2015-07-30 | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017106489A RU2017106489A (ru) | 2018-09-04 |
| RU2017106489A3 true RU2017106489A3 (enExample) | 2019-01-28 |
| RU2708391C2 RU2708391C2 (ru) | 2019-12-06 |
Family
ID=51257440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017106489A RU2708391C2 (ru) | 2014-08-01 | 2015-07-30 | 6,7-дигидропиразоло[1,5-а]пиразин-4(5h)-оновые соединения и их применение в качестве отрицательных аллостерических модуляторов рецепторов mglur2 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10220032B2 (enExample) |
| EP (1) | EP3174882B1 (enExample) |
| JP (1) | JP6517340B2 (enExample) |
| CN (1) | CN107018661B (enExample) |
| AU (1) | AU2015295300B2 (enExample) |
| CA (1) | CA2954091C (enExample) |
| ES (1) | ES2707525T3 (enExample) |
| RU (1) | RU2708391C2 (enExample) |
| WO (1) | WO2016016382A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3601B1 (ar) * | 2014-08-01 | 2020-07-05 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| CN107001373B (zh) * | 2014-08-01 | 2020-01-07 | 詹森药业有限公司 | 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负向别构调节剂的用途 |
| AU2015357169B2 (en) | 2014-12-03 | 2021-03-04 | Janssen Pharmaceutica Nv | Radiolabelled mGluR2 PET ligands |
| EP3227295B1 (en) * | 2014-12-03 | 2019-02-20 | Janssen Pharmaceutica NV | 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors |
| RS60981B1 (sr) | 2015-12-18 | 2020-11-30 | Janssen Pharmaceutica Nv | Radiooznačeni mglur2/3 pet ligandi |
| EA037941B1 (ru) | 2015-12-18 | 2021-06-09 | Янссен Фармацевтика Нв | ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ |
| MY201041A (en) | 2017-11-24 | 2024-01-31 | Sumitomo Pharma Co Ltd | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group ii metabotropic glutamate receptor |
| JP7266010B2 (ja) | 2019-05-30 | 2023-04-27 | 住友ファーマ株式会社 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体又はその塩を含有する医薬 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7329662B2 (en) * | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| ATE463495T1 (de) * | 2005-09-27 | 2010-04-15 | Hoffmann La Roche | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten |
| GB0625827D0 (en) * | 2006-12-22 | 2007-02-07 | Astex Therapeutics Ltd | New compounds |
| HRP20131122T1 (hr) | 2009-05-12 | 2013-12-20 | Janssen Pharmaceuticals, Inc. | Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja |
| JP2013529643A (ja) * | 2010-06-23 | 2013-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用なピロロピラジン誘導体 |
| EP2651222A4 (en) * | 2010-12-17 | 2014-04-30 | Univ Vanderbilt | BICYCLIC TRIAZOL AND PYRAZOLLACTAME AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS |
| US9278960B2 (en) | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
| EP2666775A1 (en) | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| US20130345204A1 (en) | 2012-06-20 | 2013-12-26 | Vanderbilt University | Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| BR112014031896A2 (pt) * | 2012-06-20 | 2017-06-27 | Univ Vanderbilt | composto, composição farmacêutica, e, método para o tratamento de um distúrbio |
| US20130345205A1 (en) | 2012-06-20 | 2013-12-26 | Vanderbilt University | Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| HK1206615A1 (en) | 2012-10-23 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Mglu2/3 antagonists for the treatment of autistic disorders |
-
2015
- 2015-07-30 RU RU2017106489A patent/RU2708391C2/ru active
- 2015-07-30 ES ES15744568T patent/ES2707525T3/es active Active
- 2015-07-30 CN CN201580041302.6A patent/CN107018661B/zh not_active Expired - Fee Related
- 2015-07-30 WO PCT/EP2015/067534 patent/WO2016016382A1/en not_active Ceased
- 2015-07-30 AU AU2015295300A patent/AU2015295300B2/en not_active Ceased
- 2015-07-30 US US15/500,234 patent/US10220032B2/en active Active
- 2015-07-30 EP EP15744568.5A patent/EP3174882B1/en active Active
- 2015-07-30 CA CA2954091A patent/CA2954091C/en active Active
- 2015-07-30 JP JP2017526014A patent/JP6517340B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-31 US US16/263,731 patent/US10668065B2/en not_active Expired - Fee Related
-
2020
- 2020-05-04 US US16/865,685 patent/US20200261450A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10220032B2 (en) | 2019-03-05 |
| AU2015295300A1 (en) | 2017-01-12 |
| US20170273976A1 (en) | 2017-09-28 |
| JP2017528515A (ja) | 2017-09-28 |
| AU2015295300B2 (en) | 2019-05-02 |
| EP3174882B1 (en) | 2018-11-07 |
| CA2954091A1 (en) | 2016-02-04 |
| US10668065B2 (en) | 2020-06-02 |
| US20190160061A1 (en) | 2019-05-30 |
| EP3174882A1 (en) | 2017-06-07 |
| CN107018661A (zh) | 2017-08-04 |
| RU2017106489A (ru) | 2018-09-04 |
| WO2016016382A1 (en) | 2016-02-04 |
| CN107018661B (zh) | 2020-01-03 |
| CA2954091C (en) | 2022-08-02 |
| US20200261450A1 (en) | 2020-08-20 |
| ES2707525T3 (es) | 2019-04-03 |
| RU2708391C2 (ru) | 2019-12-06 |
| JP6517340B2 (ja) | 2019-05-22 |